Duration Risk Explained: Why the Same Rate Move Crushed Biotech and Left Big Pharma Untouched

Minus 63.5 percent. That's how far an entire growth sector collapsed in under three years -- while a group of blue-chip dividend payers sitting right next to it barely blinked and kept paying out. Same market. Same country. Same interest rates. And yet one side was in free fall while the other stood like a rock.

That's not a coincidence. It's a mechanism -- and once you understand it, you can spot it in almost any sector, from small-cap biotech to REITs to shipping stocks.

1. Two Companies, One Interest Rate, Two Completely Different Outcomes

Picture two businesses. Company A is a large, established pharmaceutical maker: profitable today, selling approved drugs for decades, paying a reliable dividend of roughly 2% to 4%. Its cash arrives now. Company B is a small biotech: no approved drug, no dividend, burning cash every quarter. Its payoff, if it ever comes, might be eight or ten years out.

Here's what most investors miss: these two don't react to rising rates a little differently -- they react in opposite directions. Company B's entire value sits in the future, and future cash is exactly what rising rates destroy.

2. The Proof: Biotech's -63.5% Collapse, 2021–2023

The clearest evidence sits in the XBI, the index tracking small- and mid-cap biotech -- essentially the purest interest-rate-sensitivity barometer in the market. In February 2021 the XBI hit a high of $174.79, with money close to free and speculative growth names euphoric. Then the Fed reversed course and rates rose sharply. By October 2023, the same index sat at $63.80 -- a drop of 63.5%, the steepest drawdown since the XBI's inception in 2006. The maximum single drawdown was measured on May 11, 2022, mid-hiking-cycle, at nearly 64% below the high.

Now the contrast that explains everything: during the 2008 financial crisis, when the Fed slashed rates to zero, biotech (the BTK index) fell only 11% between December 2007 and June 2009 -- while the broad S&P 500 lost 37% over the same window. Biotech was the safe haven that time. Same sector, once a rock and once a free fall. The difference wasn't the companies -- it was the direction rates were moving.

3. Why the Pattern Fires Sometimes -- and Not Always

So falling rates are good for biotech, rising rates are poison -- simple, right? Not quite, and this is exactly where most investors lose money chasing the headline. In 2019, the Fed delivered three modest "insurance cuts" and the XBI gained 32.56% for the year -- a direct hit. In 2024, the Fed cut rates for the first time in September; by the same logic biotech should have taken off. Full-year result: +1.01%. Essentially nothing. A brief spike on the cut itself, then the index closed the year roughly where it started, near $100. The pattern simply didn't fire.

Why? Because it was never about the cut itself -- it's about timing and expectation. The real pattern: biotech tends to outperform in the months before the first cut, as the market prices it in; right after, it often underperforms for about a month (classic sell-the-news); then, over the following six to twelve months, gains of roughly 20% to 30% typically follow. And it isn't purely a rate story either: in 2025 the XBI rose 35% -- up 75% from its April low -- with no rate cut at all. Rates are the single strongest lever for duration-sensitive sectors, but never the only one.

4. The Mechanic: Duration in Plain English

Here's the mechanism. Every stock is, at its core, a claim on future cash. To know what future cash is worth today, you discount it -- and the interest rate is the discount rate. When rates rise, the present value of money that arrives far in the future shrinks, and the effect is brutal for anything whose payday sits many years out.

The math: a 3-percentage-point increase in the discount rate can cut a project's net present value (NPV) by roughly 32% to 70% -- the longer the runway to commercialization, the closer you get to that 70% end. Three points is not an extreme scenario; it's roughly what a single Fed hiking cycle can deliver. That means a 3-point rate move can erase up to 70% of a future-focused business's present-day value without a single thing changing about the underlying business -- same drug, same pipeline, same team, only the discount rate moved. It's the same discounting logic behind the Dividend Discount Model used to value income stocks.

Big Pharma sits on the opposite end: most of its cash arrives now, so the discounting effect barely bites. That's the anchor behind the "boring, stable dividend payer" reputation.

5. Big Pharma vs. Biotech: The Cheat Sheet

A quick note before the table: the names below (Pfizer, Bristol-Myers, AbbVie, Johnson & Johnson) appear purely as real-world examples of the mechanic -- this is not a buy recommendation for any of them, individually or as a group.

6. The Duration Check: 3 Questions for Any Sector

Now the useful part. You don't need a finance degree to run this check on any stock or sector -- just three questions.

Run those three questions on any sector and the duration pattern becomes visible almost everywhere.

7. The Bridge to Hard Assets: REITs vs. Shipping and Commodities

This logic isn't limited to pharma versus biotech -- it explains nearly every hard-asset sector, and it's a big part of why I build my own portfolio the way I do.

REITs sit closer to biotech in duration terms than most investors assume. A property is essentially a long stream of future rental income -- long duration, plus real debt on top. Rising rates hit REITs twice: future rents get discounted harder, and refinancing gets more expensive. Same mechanic as biotech, just built from concrete instead of molecules (see our MPW analysis for a real example).

Shipping and commodities often behave the opposite way. A tanker earns its money right now, at today's spot rates -- short duration. And rates usually rise because the economy is running hot and inflation is elevated, which is often exactly the environment that pushes freight rates and commodity prices higher. That's why shipping, energy, and commodities sit at the core of a hard-asset, dividend-focused portfolio: the natural counterweight to duration-heavy growth assets. You don't need to own every sector, but knowing which of your holdings are duration-exposed -- and which benefit from the same rate move -- is the difference between a random collection of stocks and a portfolio you understand.

8. Today's Regime: Why This Matters Right Now

This isn't a history lesson -- it's the current setup. The Fed funds range currently sits at 3.5%–3.75%, with no rate cut visible on the 2026 calendar. Goldman Sachs doesn't see the next cut until 2027, and markets have at times priced in the risk of a hike instead, since the Iran conflict has kept oil and gas elevated and core PCE inflation ran at 3.4% in May -- the highest reading in roughly three years.

Translated into the duration framework: this is not an environment where long-duration bets get rewarded, and there's no falling-rate tailwind pulling future-focused growth stories higher right now. If anything, the regime leans against long-duration assets and potentially favors the short-duration side -- energy, shipping, commodities. I'm not telling you what to buy. But knowing which interest-rate regime you're in tells you which part of your portfolio has the wind at its back right now, and which part is fighting against it. That's what cycle recognition actually means.

AuthorMarco Bozem

Independent hard-asset investor since 2022. Covers dividends from shipping, mining, energy & pipelines from a real private-investor portfolio — with disclosed positions on every analysis.

About Marco →YouTubeLinkedIn